Free Trial

D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma logo with Medical background

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reiterated by D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital's target price points to a potential upside of 82.35% from the stock's previous close.

Other research analysts also recently issued reports about the company. HC Wainwright upgraded Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price objective on the stock in a report on Monday, June 16th. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. Finally, Guggenheim reiterated a "buy" rating and issued a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $32.86.

Read Our Latest Stock Report on URGN

Urogen Pharma Stock Performance

URGN traded up $0.22 during trading on Monday, hitting $13.71. 827,939 shares of the stock were exchanged, compared to its average volume of 1,082,523. The firm has a 50 day simple moving average of $9.72 and a 200 day simple moving average of $10.26. The firm has a market cap of $632.17 million, a price-to-earnings ratio of -4.31 and a beta of 1.02. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $18.15.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. As a group, equities analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the sale, the insider owned 153,378 shares of the company's stock, valued at approximately $1,130,395.86. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.10% of the company's stock.

Institutional Trading of Urogen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. CWM LLC lifted its position in Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after acquiring an additional 5,140 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Urogen Pharma during the 4th quarter worth about $59,000. Lazard Asset Management LLC acquired a new stake in Urogen Pharma during the 4th quarter worth about $67,000. GAMMA Investing LLC raised its stake in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in shares of Urogen Pharma during the 4th quarter valued at about $101,000. Institutional investors and hedge funds own 91.29% of the company's stock.

About Urogen Pharma

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Further Reading

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Should You Invest $1,000 in Urogen Pharma Right Now?

Before you consider Urogen Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.

While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines